MetaCap

SciSparc (SPRC) vs China SXT Pharmaceuticals (SXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SciSparc is the larger company by market cap ($481,603 vs $273,955), about 1.8 times the size, while China SXT Pharmaceuticals is growing revenue faster (-34.6% vs -54.6%). SciSparc converts more of its revenue into profit, with a net margin of -481.2% versus -545.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SPRC-95.79%SXTC-6.54%
+36%-34%-105%
Oct 7, 20261 yearNov 20, 2026
SPRC-95.63%SXTC+1678.75%
+2195%+995%-205%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SPRC versus SXTC key metrics
MetricSPRCSXTC
Share price$0.1955$2.65
Market cap$481.60K$273.95K
1-day change-34.83%+2.12%
P/E ratio (TTM)0.00—
EPS (TTM)$248.24$-73,040.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.31M$1.14M
Revenue growth (YoY)-54.64%-34.63%
Net income (latest FY)$-6.28M$-6.21M
Gross margin38.74%21.85%
Operating margin-560.18%-625.89%
Net margin-481.16%-545.24%
52-week high$29.88$8,376,000.00
52-week low$0.167$2.52
Distance from 52-week high-99.35%-100.00%
Average volume2.93M234.25K
Shares outstanding2.46M103.58K
Employees356
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SciSparc is more profitable, keeping -481.2 cents of every revenue dollar as net income versus -545.2 cents for China SXT Pharmaceuticals.
  • China SXT Pharmaceuticals grew revenue faster in its latest fiscal year (-34.63% vs -54.64%).

About SciSparc

SPRC stock →

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About China SXT Pharmaceuticals

SXTC stock →

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

SPRC vs SXTC FAQ

Which is bigger, SciSparc or China SXT Pharmaceuticals?

SciSparc (SPRC) is larger, with a market capitalization of $481.60K compared with $273.95K for China SXT Pharmaceuticals (SXTC).

Are SciSparc and China SXT Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons